BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20609177)

  • 1. To treat or not to treat renal anemia of chronic kidney disease patients?
    Tsubakihara Y
    Ther Apher Dial; 2010 Jun; 14(3):235-9. PubMed ID: 20609177
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anemia in chronic renal failure and erythropoietin].
    Rosenlöf K
    Duodecim; 1995; 111(15):1489-95. PubMed ID: 9244705
    [No Abstract]   [Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
    Kessler M
    Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
    [No Abstract]   [Full Text] [Related]  

  • 7. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease.
    Fishbane S
    Blood Purif; 2007; 25(1):53-7. PubMed ID: 17170538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing anemia. What do we do now? Views from Canada.
    Mendelssohn DC; Muirhead N; Manns BJ
    Nephrol News Issues; 2007 Jun; 21(7):55-7. PubMed ID: 17623988
    [No Abstract]   [Full Text] [Related]  

  • 9. Do hemodialysis patients need higher doses of erythropoietin if given intravenously rather than subcutaneously?
    McMahon LP
    Nat Clin Pract Nephrol; 2006 May; 2(5):246-7. PubMed ID: 16932434
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapeutic guidelines for renal anemia in Japan].
    Naito M; Akiba T
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():562-5. PubMed ID: 15250369
    [No Abstract]   [Full Text] [Related]  

  • 11. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS; Pratt RD;
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EPO/iron marriage: counseling needed.
    Bralow S
    Nephrol News Issues; 2007 Jun; 21(7):53, 55. PubMed ID: 17623987
    [No Abstract]   [Full Text] [Related]  

  • 13. [Role of renal anemia in progression of chronic kidney disease].
    Racki S; Maleta I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction to "A road map for intravenous iron and anemia management: preparing for the future".
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S1-4. PubMed ID: 19010256
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
    Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
    Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
    [No Abstract]   [Full Text] [Related]  

  • 16. [Case of early pronounced anemia and its effective treatment with human recombinant erythropoietin in a female patient with polycystic kidney in a conservative stage of chronic renal failure].
    Alekseeva TB; Nikolaev AIu; Trofimova EI
    Ter Arkh; 1999; 71(6):70-1. PubMed ID: 10420463
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemoglobin variability in dialysis patients.
    Brimble KS; Clase CM
    J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
    Kanbay M; Perazella MA; Kasapoglu B; Koroglu M; Covic A
    Blood Purif; 2010; 29(1):1-12. PubMed ID: 19816014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin and its use in renal failure.
    Sulková S; Krajhanzl A
    EDTNA ERCA J; 1996; 22(1):suppl 1-7; quiz 8. PubMed ID: 10723310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target hemoglobin level for EPO therapy in CKD.
    Parfrey PS
    Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.